These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 9250454

  • 1. Metabolic efficacy of preprandial administration of Lys(B28), Pro(B29) human insulin analog in IDDM patients. A comparison with human regular insulin during a three-meal test period.
    Jacobs MA, Keulen ET, Kanc K, Casteleijn S, Scheffer P, Devillé W, Heine RJ.
    Diabetes Care; 1997 Aug; 20(8):1279-86. PubMed ID: 9250454
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Optimization of evening insulin dose in patients using the short-acting insulin analog lispro.
    Ahmed AB, Mallias J, Home PD.
    Diabetes Care; 1998 Jul; 21(7):1162-6. PubMed ID: 9653613
    [Abstract] [Full Text] [Related]

  • 5. Effects of the short-acting insulin analog [Lys(B28),Pro(B29)] on postprandial blood glucose control in IDDM.
    Torlone E, Pampanelli S, Lalli C, Del Sindaco P, Di Vincenzo A, Rambotti AM, Modarelli F, Epifano L, Kassi G, Perriello G, Brunetti P, Bolli G.
    Diabetes Care; 1996 Sep; 19(9):945-52. PubMed ID: 8875087
    [Abstract] [Full Text] [Related]

  • 6. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
    Tîrgovişte CI, Străchinariu R, Farcaşiu E, Milicevic Z, Teodorescu G.
    Rom J Intern Med; 2003 Sep; 41(2):153-62. PubMed ID: 15526500
    [Abstract] [Full Text] [Related]

  • 7. Human insulin analogue [LYS(B28), PRO(B29)]: the ideal pump insulin?
    Schmauss S, König A, Landgraf R.
    Diabet Med; 1998 Mar; 15(3):247-9. PubMed ID: 9545126
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime.
    Rossetti P, Pampanelli S, Fanelli C, Porcellati F, Costa E, Torlone E, Scionti L, Bolli GB.
    Diabetes Care; 2003 May; 26(5):1490-6. PubMed ID: 12716810
    [Abstract] [Full Text] [Related]

  • 11. Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime.
    Lalli C, Ciofetta M, Del Sindaco P, Torlone E, Pampanelli S, Compagnucci P, Cartechini MG, Bartocci L, Brunetti P, Bolli GB.
    Diabetes Care; 1999 Mar; 22(3):468-77. PubMed ID: 10097931
    [Abstract] [Full Text] [Related]

  • 12. Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.
    Weyer C, Gottlieb A, Kim DD, Lutz K, Schwartz S, Gutierrez M, Wang Y, Ruggles JA, Kolterman OG, Maggs DG.
    Diabetes Care; 2003 Nov; 26(11):3074-9. PubMed ID: 14578242
    [Abstract] [Full Text] [Related]

  • 13. Comparison of lunch and bedtime NPH insulin plus mealtime insulin Lispro therapy with premeal regular insulin plus bedtime NPH insulin therapy in type 2 diabetes.
    Sargin H, Sargin M, Altuntaş Y, Sengül AM, Orbay E, Seber S, Uçak S, Yayla A.
    Diabetes Res Clin Pract; 2003 Nov; 62(2):79-86. PubMed ID: 14581144
    [Abstract] [Full Text] [Related]

  • 14. The effect of the insulin analog lispro on nighttime blood glucose control in type 1 diabetic patients.
    Ahmed AB, Home PD.
    Diabetes Care; 1998 Jan; 21(1):32-7. PubMed ID: 9538967
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Prandial glycaemia after a carbohydrate-rich meal in type I diabetic patients: using the rapid acting insulin analogue [Lys(B28), Pro(B29)] human insulin.
    Heinemann L, Heise T, Wahl LC, Trautmann ME, Ampudia J, Starke AA, Berger M.
    Diabet Med; 1996 Jul; 13(7):625-9. PubMed ID: 8840095
    [Abstract] [Full Text] [Related]

  • 17. Strategies toward improved control during insulin lispro therapy in IDDM. Importance of basal insulin.
    Ebeling P, Jansson PA, Smith U, Lalli C, Bolli GB, Koivisto VA.
    Diabetes Care; 1997 Aug; 20(8):1287-9. PubMed ID: 9250455
    [Abstract] [Full Text] [Related]

  • 18. Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group.
    Renner R, Pfützner A, Trautmann M, Harzer O, Sauter K, Landgraf R.
    Diabetes Care; 1999 May; 22(5):784-8. PubMed ID: 10332682
    [Abstract] [Full Text] [Related]

  • 19. Insulin lispro in CSII: results of a double-blind crossover study.
    Zinman B, Tildesley H, Chiasson JL, Tsui E, Strack T.
    Diabetes; 1997 Mar; 46(3):440-3. PubMed ID: 9032100
    [Abstract] [Full Text] [Related]

  • 20. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group.
    Anderson JH, Brunelle RL, Keohane P, Koivisto VA, Trautmann ME, Vignati L, DiMarchi R.
    Arch Intern Med; 1997 Jun 09; 157(11):1249-55. PubMed ID: 9183237
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.